Navigation Links
Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego
Date:1/17/2012

SAN DIEGO, Jan. 17, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen) today opens Janssen Labs at San Diego, a 30,000-square-foot life science innovation center, located within the company's Janssen West Coast Research Center.  The innovation center provides a capital efficient, flexible lab environment for start-up companies pursuing new technologies and research platforms to advance medical care.

(Logo: http://photos.prnewswire.com/prnh/20120117/LA36598LOGO)

"A thriving biotech ecosystem is crucial for the success of the pharmaceutical industry as a whole," said Diego Miralles, M.D., site head for the West Coast Research Center.  "Recent challenges in the economic environment have made it difficult for many emerging biotech companies.  We believe that supporting and nurturing these companies will be good for the entire industry."

San Diego Mayor Jerry Sanders will present Janssen with a commendation in recognition of their contributions to the vibrant and growing life science industry in San Diego.

"This new venture is part of our overall strategy to spur innovation, and underscores our commitment to advance novel discoveries quickly and efficiently from the bench to the patient bedside," said Miralles. "By providing a flexible and cost-efficient way to test new ideas, Janssen Labs provides early stage companies a way to overcome the typical hurdles faced by start-up companies, which are even greater in the current economic climate." 

The Janssen Labs model provides small companies many of the advantages of being in a big company, without the capital investment.  Companies can license for space and equipment modular wet lab units on a short-term renewable basis and only pay for the space that they need, with an option to quickly expand when they have the resources to do so.  The companies will also have access to core research labs hosting specialized capital equipment and core administrative areas maintained by Janssen Labs operations management team.

"This arrangement allows the companies to focus on the development of the science instead of setting up and managing the labs," said Miralles.  "We believe this open innovation model will minimize cost and time and is an effective way for companies to develop and focus on research."

Because Janssen Labs is an open innovation model, the agreement for the space does not grant Janssen any stake in the companies nor will the companies have a guaranteed future affiliation with Janssen.
If either Janssen or a residing company is interested in furthering the business relationship, the process would be the same as for any external partnership or collaboration. 

To date, the management team of Janssen Labs has received and reviewed more than 100 applications. Companies are evaluated based on criteria such as compelling science and/or technology, area of significant medical or market need, credible science/technology team, demonstrated financial solvency, etc.  The applying companies represent diverse sectors across healthcare including biotech, pharmaceuticals, medical devices, instrumentation and diagnostics.  The facility can accommodate a maximum of 18 to 20 companies, and the application and assessment process will continue throughout 2012."We are pleased by the overwhelmingly positive response since we announced our plans to open Janssen Labs at San Diego a few months ago," says Miralles.  "Across sectors, stages and geographies, entrepreneurs and start-up companies are interested in this 'no-strings-attached' capital-efficient model to progress their scientific work.  Our goal with Janssen Labs is to give novel technologies a greater opportunity to reach the patient by reducing some of the hurdles of early stage discovery."

Janssen's operational management of Janssen Labs will be supported by Prescience International, an external firm that specializes in setting up and operating innovation centers in life sciences. 

The following companies are the first to be selected to become residents of Janssen Labs: CompanyLeadershipTechnologyDiomics

Dr. Jeff Morhet

Dennison Business Leader of the Year Award for his work in innovative entrepreneurialism

Diagnostics, forensics, integrated DNA analysis and genetic solutionsNeurolixis

Dr. Adrian Newman-Tancredi

 

Chief Scientific Officer

To design and develop novel small molecule compounds against a number of targets in the CNS targeting treatment-resistant depression, cognitive deficits in schizophrenia and symptomatic treatment of Parkinson's disease. Tem Systems

Dr. Robert Hillman

 

Founder and CEO of Accumetrics, ActivX BioSciences (acquired by Kyorin Inc), Founder Biotrack (acquired by Boehringer Mannheim), Ph.D.

Medical diagnostic systems that provide a comprehensive profile of a patient's coagulation status.Yolia Health

Alberto Osio, CEO and Founder

 

Yolia's co-founders, Alberto and Eduardo Osio (siblings) have been named by CNN Expansion, Mexico's Top Entrepreneurs of the year in 2007 and 2010

Optometric devices for cost-effective, non-invasive forms of treatment Janssen Research & Development, LLCJanssen Research & Development, LLC, (Janssen), is one of the Janssen Pharmaceutical Companies.  Janssen is headquartered in Raritan, N.J., and has facilities in Europe, the United States and Asia. Janssen is leveraging drug discovery and drug development in a variety of therapeutic areas, including Neuroscience, Oncology, Immunology, Infectious Diseases, and Cardiovascular and Metabolism to address unmet medical needs worldwide.More information can be found at http://www.janssenrnd.com/our-innovation/partnerships/janssen-labs-at-san-diego.

 

 


'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
2. Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied
3. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
6. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
7. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
8. Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
10. Record Breaking $327 Million Verdict Announced in Janssen Case
11. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... , May 3, 2016 BioNovus Innovations ... Institute for Advancing Medical Innovation (IAMI) today announced ... drugs, diagnostics and medical devices. An ... with rights to license, develop and commercialize medical ... "This partnership represents a significant advance ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a ... it can weaken the immune system and increase inflammation, both of which raise the ... the adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the 2016 ... Texas. , Scott Pettigrew, Vice President and Chief Security Officer of HMS, ...
(Date:5/5/2016)... ... ... If you don’t mind a bit of prickly therapy to help combat acne ... treatment that some have called the next great tool in dermatology – microneedling, says ... skin needling, is a procedure using a device covered with tiny, shallow needles to ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pigment Laser Tattoo Removal Center is ... of the new PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. ... other picosecond laser on the market. Jeremy Miller, Tattoo Artist and former reality ...
(Date:5/5/2016)... GA (PRWEB) , ... May 05, 2016 , ... Liposuction ... (FDRS) 2016 Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. ... Byrd was chosen to address the conference about her unique specialization in treating Lipedema. ...
Breaking Medicine News(10 mins):